Table 2.
HbA1c levels at week 0, week 28 (teneligliptin 20 mg), and week 52 (teneligliptin 40 mg), and proportion of patients achieving HbA1c target < 7% with teneligliptin 40 mg
| All | Response or not to dose increase | Re-elevation or not during 20 mg treatment | |||||
|---|---|---|---|---|---|---|---|
| HbA1c ≥ 0.1% (re-elevation) | HbA1c < 0.1% (no re-elevation) | ||||||
| HbA1c ≤ − 0.1% (response) |
HbA1c > − 0.1% (no response) |
HbA1c ≤ − 0.1% (response) |
HbA1c > − 0.1% (no response) |
HbA1c ≤ − 0.1% (response) |
HbA1c > − 0.1% (no response) |
||
| Number of patients | 204 | 108 | 96 | 89 | 54 | 19 | 42 |
| HbA1c, % | |||||||
| Week 0 | 8.57 (0.77) | 8.61 (0.73) | 8.53 (0.81) | 8.61 (0.75) | 8.42 (0.74) | 8.66 (0.67) | 8.67 (0.87) |
| Week 28 | 7.93 (0.69) | 8.01 (0.71) | 7.83 (0.65) | 8.14 (0.71) | 7.99 (0.64) | 7.42 (0.28) | 7.63 (0.61) |
| Week 52 (LOCF) | 7.85 (0.85) | 7.51 (0.75) | 8.23 (0.80) | 7.62 (0.77) | 8.34 (0.76) | 7.02 (0.39) | 8.09 (0.85) |
| ∆ 0–28 weeks | − 0.64 (0.73) | − 0.60 (0.74) | − 0.69 (0.72) | − 0.46 (0.69) | − 0.42 (0.71) | − 1.24 (0.62) | − 1.04 (0.56) |
| ∆ 0–52 weeks (LOCF) | − 0.73 (0.92) | − 1.10 (0.84) | − 0.30 (0.81) | − 0.99 (0.80) | − 0.08 (0.80) | − 1.64 (0.86) | − 0.58 (0.74) |
| ∆ 28–52 weeks (LOCF) | − 0.08 (0.62) | − 0.50 (0.44) | 0.39 (0.41) | − 0.53 (0.45) | 0.34 (0.32) | − 0.39 (0.41) | 0.46 (0.49) |
| % of patients with HbA1c < 7.0% at week 52 | 10.9 | 20.4 | – | 18.0 | – | 31.6 | – |
Data are mean (SD) unless otherwise stated
HbA1c glycated hemoglobin, LOCF last observation carried forward, SD standard deviation